These data suggest that the enhanced tumor phenotypes in RBBP9-deficient mice do not depend on Wnt/β-catenin signaling activation but rather on the mTORC1 and IL6/JAK/STAT3 signaling pathways. This evidence concerns the gene IL6 and neoplasm.